1d agoThe FlyBULLISH 58Analyst
Archived explainer. For the current picture see today's NEOG page.
Why Is NEOGEN CORP (NEOG) Stock Down Today?
By the Top Tier Newswire AI Desk · September 29, 2026 at 2:22 PM ET · reviewed against 4 wire stories
NEOGEN CORP (NEOG) is down -5.50% in the latest session. Our newswire has captured 4 stories on NEOG across 3 sources in the last 36 hours, with AI sentiment reading bearish (avg 40/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
NEOG stock fell 5.50% to $12.97 in early trading after the U.S. Food and Drug Administration issued a warning letter to Neogen regarding its veterinary product Hycoat. The letter cited contamination concerns linked to horse deaths and described the product as a veterinary medical device that was not properly sterile. The stock opened at $13.66 and quickly declined to a session low of $12.86 before stabilizing slightly in the last hours of the session.
What Happened
The FDA warning letter, which was first reported by Morningstar and later covered by Seeking Alpha and The Fly, triggered the selloff. The letter states that the agency's investigation found contamination of Neogen’s Hycoat product, which is marketed as a sterile topical wound solution for surgical wounds and burns. The FDA linked the contamination to a significant number of horse deaths, calling it the largest incident of its kind involving an FDA-regulated veterinary product. The company has not issued a formal response yet, but Guggenheim analysts suggested the selloff is overdone, according to The Fly. Meanwhile, Benzinga reported that traders are circulating an unconfirmed analyst report defending Neogen, noting that Hycoat is third-party manufactured and that the revenue impact is immaterial.
What The Data Shows
The stock traded at 2.1 times its 3-month average volume, indicating heightened interest. With a market cap of $3.0B and a recent earnings loss of $0.04 per share, Neogen is currently unprofitable. The stock has traded between $5.32 and $14.26 over the past 52 weeks. On the 52-week tape, the stock hit 15 fresh 52-week lows on September 29. The CEO, Nassif Mikheal, has made one insider purchase totaling $4K in the last 90 days, according to SEC filings.
What To Watch
Neogen is scheduled to report Q1 earnings soon, and analysts will be watching for any updates on the FDA investigation and Hycoat’s status. Coverage breadth and sentiment shifts will also be key indicators for the stock’s near-term direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NEOG by the numbers
Last: $12.97Session: -5.50%Coverage: 4 stories / 3 sourcesAI sentiment: 40/100 (bearish)Mkt cap: $3.0B52w: $5.32 to $14.26
The headlines behind the move
1d agoThe FlyBEARISH 34General
Neogen issued FDA warning letter for Neogen Vet HYCOAT
1d agoMorningstarBEARISH 34General
Neogen Gets FDA Warning After Probe Links Vet Product to Horse Deaths
Hycoat is marketed by Neogen as a vet device and is labeled as a sterile topical wound management solution intended for use on surgical wounds, burns and similar conditions. It is packaged in a glass vial with a septum top.
1d agoSeeking AlphaBEARISH 34General
Neogen gets FDA warning letter over horse deaths linked to Hycoat
Neogen (NEOG) shares dip after FDA warning letters over recalled Hycoat linked to horse deaths and contamination.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on NEOG: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier NEOG move explainers: 2026-09-30 · 2026-09-29